NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

RecruitingPhase 1, Phase 2

Sponsor: Recursion Pharmaceuticals Inc.

Conditions: Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas

Interventions: REC-1245

Countries: United States, Canada

This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

Eligibility overview

Sex: ALL

Age: 12 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma
* Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.
* Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70.
* Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI)

Exclusion Criteria:

* Received treatment with another RBM39 degrader
* Clinically significant gastrointestinal (GI) or GI malabsorption

Locations (7)

Duarte, California, United States
Santa Monica, California, United States
Cleveland, Ohio, United States
Nashville, Tennessee, United States
West Valley City, Utah, United States
Toronto, Ontario, Canada
Québec, Canada